Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3288565 | Gastroenterología y Hepatología | 2011 | 5 Pages |
Abstract
Based on this clinical experience and a review of the literature comparing infliximab with other pharmacological options, we believe that this drug should be the treatment of choice in patients with Crohn's disease who develop severe lower gastrointestinal bleeding. This strategy can, in some cases, avoid surgery if the bleeding stops due to rapid healing of the deep mucosal lesions causing the hemorrhagic episode.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Alfonso Alcalde Vargas, José Manuel Herrera Justiniano, Eduardo Leo Carnerero, Claudio Trigo Salado, Ignacio Gutiérrez Domingo, José Luis Márquez Galán,